Experienced in Lung Nodules

Dr. Elhamy D. Eskander

Oncology | Hematology | Hematology Oncology
Frederick Health Medical Group LLC
1562 Opossumtown Pike, 
Frederick, MD 
Accepting New Patients
Experienced in Lung Nodules
Frederick Health Medical Group LLC
1562 Opossumtown Pike, 
Frederick, MD 
OverviewInsuranceLocationsClinical Research

Overview

Elhamy Eskander is an Oncologist and a Hematologist in Frederick, Maryland. Dr. Eskander and is rated as an Experienced provider by MediFind in the treatment of Lung Nodules. His top areas of expertise are Lung Cancer, Childhood Iron Deficiency Anemia, Pleuropulmonary Blastoma, and Autoimmune Hemolytic Anemia. Dr. Eskander is currently accepting new patients.

His clinical research consists of participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Hematology Oncology
Licenses
Internal Medicine in MD
Hospital Affiliations
Frederick Health Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Aetna
  •  CareFirst
  •  UnitedHealthcare
  •  Humana

Locations

FREDERICK HEALTH MEDICAL GROUP LLC
1562 Opossumtown Pike, Frederick, MD 21702

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Etoposide, Nivolumab
Study Phase: Phase 2
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drugs: Zimberelimab, Domvanalimab, Etrumadenant
Study Phase: Phase 2
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 02, 2024
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
Enrollment Status: Terminated
Publish Date: January 20, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Enrollment Status: Terminated
Publish Date: September 11, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2
View 8 Less Clinical Trials
Similar Doctors
Experienced in Lung Nodules
Dr. Gurdeep S. Chhabra
Hematology Oncology | Hematology | Oncology
Experienced in Lung Nodules
Dr. Gurdeep S. Chhabra
Hematology Oncology | Hematology | Oncology

Medstar Medical Group - Southern Maryland LLC

6510 Kenilworth Ave, Suite 2100, 
Riverdale Park, MD 
 (41.7 mi)
301-373-7900
Languages Spoken:
English, French, Hindi, Punjabi
See accepted insurances
Accepting New Patients

Gurdeep Chhabra is a Hematologist Oncology specialist and a Hematologist in Riverdale Park, Maryland. Dr. Chhabra and is rated as a Distinguished provider by MediFind in the treatment of Lung Nodules. His top areas of expertise are Inflammatory Breast Cancer, Paget Disease of the Breast, Colorectal Cancer, and Small Cell Lung Cancer (SCLC). Dr. Chhabra is currently accepting new patients.

Experienced in Lung Nodules
Dr. Qiwei W. Gai
Hematology Oncology | Public Health and Preventive Medicine | Hematology
Experienced in Lung Nodules
Dr. Qiwei W. Gai
Hematology Oncology | Public Health and Preventive Medicine | Hematology

Carroll Regional Cancer Center Physicians, LLC

291 Stoner Ave, 
Westminster, MD 
 (23.8 mi)
410-871-6400
Languages Spoken:
English, Mandarin
See accepted insurances
Accepting New Patients

Qiwei Gai is a Hematologist Oncology specialist and a Public Health and Preventive Medicine provider in Westminster, Maryland. Dr. Gai and is rated as a Distinguished provider by MediFind in the treatment of Lung Nodules. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Lung Cancer, Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Gai is currently accepting new patients.

Experienced in Lung Nodules
Dr. Yudhishtra Markan
Hematology Oncology | Hematology | Oncology
Experienced in Lung Nodules
Dr. Yudhishtra Markan
Hematology Oncology | Hematology | Oncology

Chesapeake Oncology Hematology Assoc

305 Hospital Dr, 
Glen Burnie, MD 
 (46.8 mi)
410-761-9896
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Yudhishtra Markan is a Hematologist Oncology specialist and a Hematologist in Glen Burnie, Maryland. Dr. Markan and is rated as a Distinguished provider by MediFind in the treatment of Lung Nodules. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Familial Colorectal Cancer, and Colorectal Cancer. Dr. Markan is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile